Arcellx Inc (ACLX) Stock Forecast & Price Target

Compare

234 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ACLX Analyst Ratings

Strong Buy

14 Buy

0 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Arcellx

Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ACLX Stock 12 Month Forecast

Average Price Target

$111.09

▲(79.38%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Arcellx Inc in the last 3 months. The average price target is $111.09 with a high forecast of $121.00 and a low forecast of $93.00. The average price target represents a 79.38% change from the last price of $61.93.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","122":"$122","68.75":"$68.8","86.5":"$86.5","104.25":"$104.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$111.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$93.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,68.75,86.5,104.25,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.53,69.79692307692308,74.06384615384616,78.33076923076923,82.59769230769231,86.86461538461539,91.13153846153847,95.39846153846153,99.66538461538462,103.93230769230769,108.19923076923078,112.46615384615384,116.73307692307692,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.53,69.03461538461539,72.53923076923077,76.04384615384616,79.54846153846154,83.05307692307693,86.5576923076923,90.0623076923077,93.56692307692308,97.07153846153847,100.57615384615386,104.08076923076923,107.58538461538461,{"y":111.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.53,67.64307692307692,69.75615384615385,71.86923076923077,73.9823076923077,76.09538461538462,78.20846153846153,80.32153846153847,82.43461538461538,84.5476923076923,86.66076923076923,88.77384615384615,90.88692307692307,{"y":93,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":52.18,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.6,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.65,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.69,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$121.00

Average Price Target$111.09

Lowest Price Target$93.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$65

Hold

4.96%

Upside

Reiterated

05/31/25

Arcellx Inc's overall stock score is driven by promising corporate events and moderate technical indicators. The financial performance poses risks due to ongoing losses, but strong cash reserves provide a buffer. Despite negative valuation metrics, the positive study results and strategic board appointments support future growth potential.

Cory KasimovEvercore ISI

Evercore ISI

$115

Buy

85.69%

Upside

Reiterated

05/15/25

Evercore ISI Sticks to Their Buy Rating for Arcellx Inc (ACLX)

George FarmerScotiabank

Scotiabank

$93

Buy

50.17%

Upside

Reiterated

05/15/25

Scotiabank Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

Emily BodnarH.C. Wainwright

H.C. Wainwright

$115

Buy

85.69%

Upside

Reiterated

05/15/25

Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc's Anito-cel Therapy

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/15/25

Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB), Lucid Diagnostics (NASDAQ: LUCD) and Arcellx Inc (NASDAQ: ACLX)

Unknown AnalystGuggenheim

Not Ranked

Guggenheim

$120

Buy

93.77%

Upside

Reiterated

05/15/25

Anito-Cel’s best-in-class safety profile continues; we remain Buy rated, PT $120.

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

Arcellx Inc's Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating

Judah FrommerMorgan Stanley

Morgan Stanley

$111

Buy

79.23%

Upside

Reiterated

05/14/25

Arcellx Inc's Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst

John NewmanCanaccord Genuity

Canaccord Genuity

$121

Buy

95.38%

Upside

Reiterated

05/14/25

Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity

Daina GrayboschLeerink Partners

Leerink Partners

$100

Buy

61.47%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (NASDAQ: CNTA), Arcellx Inc (NASDAQ: ACLX) and Belite Bio, Inc. ADR (NASDAQ: BLTE)

Gil BlumNeedham

Needham

$105

Buy

69.55%

Upside

Reiterated

05/14/25

Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc's Anito-cel

Biren AminPiper Sandler

Piper Sandler

$115

Buy

85.69%

Upside

Reiterated

05/09/25

Piper Sandler Remains a Buy on Arcellx Inc (ACLX)

Peter LawsonBarclays

Barclays

$115

Buy

85.69%

Upside

Reiterated

05/09/25

Barclays Keeps Their Buy Rating on Arcellx Inc (ACLX)

Jason GerberryBank of America Securities

Bank of America Securities

$112

Buy

80.85%

Upside

Reiterated

05/08/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (NASDAQ: ACLX), Vir Biotechnology (NASDAQ: VIR) and Liquidia Technologies (NASDAQ: LQDA)

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Promising Potential of Arcellx Inc's Anito-cel Program Drives Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$65

Hold

4.96%

Upside

Reiterated

05/31/25

Cory KasimovEvercore ISI

Evercore ISI

$115

Buy

85.69%

Upside

Reiterated

05/15/25

Evercore ISI Sticks to Their Buy Rating for Arcellx Inc (ACLX)

George FarmerScotiabank

Scotiabank

$93

Buy

50.17%

Upside

Reiterated

05/15/25

Scotiabank Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

Emily BodnarH.C. Wainwright

H.C. Wainwright

$115

Buy

85.69%

Upside

Reiterated

05/15/25

Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc's Anito-cel Therapy

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/15/25

Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB), Lucid Diagnostics (NASDAQ: LUCD) and Arcellx Inc (NASDAQ: ACLX)

Unknown AnalystGuggenheim

Not Ranked

Guggenheim

$120

Buy

93.77%

Upside

Reiterated

05/15/25

Anito-Cel’s best-in-class safety profile continues; we remain Buy rated, PT $120.

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

Arcellx Inc's Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating

Judah FrommerMorgan Stanley

Morgan Stanley

$111

Buy

79.23%

Upside

Reiterated

05/14/25

Arcellx Inc's Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst

John NewmanCanaccord Genuity

Canaccord Genuity

$121

Buy

95.38%

Upside

Reiterated

05/14/25

Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity

Daina GrayboschLeerink Partners

Leerink Partners

$100

Buy

61.47%

Upside

Reiterated

05/14/25

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (NASDAQ: CNTA), Arcellx Inc (NASDAQ: ACLX) and Belite Bio, Inc. ADR (NASDAQ: BLTE)

Gil BlumNeedham

Needham

$105

Buy

69.55%

Upside

Reiterated

05/14/25

Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc's Anito-cel

Biren AminPiper Sandler

Piper Sandler

$115

Buy

85.69%

Upside

Reiterated

05/09/25

Piper Sandler Remains a Buy on Arcellx Inc (ACLX)

Peter LawsonBarclays

Barclays

$115

Buy

85.69%

Upside

Reiterated

05/09/25

Barclays Keeps Their Buy Rating on Arcellx Inc (ACLX)

Jason GerberryBank of America Securities

Bank of America Securities

$112

Buy

80.85%

Upside

Reiterated

05/08/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (NASDAQ: ACLX), Vir Biotechnology (NASDAQ: VIR) and Liquidia Technologies (NASDAQ: LQDA)

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Promising Potential of Arcellx Inc's Anito-cel Program Drives Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcellx Inc

1 Month

xxx

Success Rate

10/13 ratings generated profit

Average Return

+5.18%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +5.18% per trade.

3 Months

xxx

Success Rate

13/20 ratings generated profit

Average Return

+14.01%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +14.01% per trade.

1 Year

Jason GerberryBank of America Securities

Success Rate

14/17 ratings generated profit

Average Return

+39.68%

reiterated a buy rating 27 days ago

Copying Jason Gerberry's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +39.68% per trade.

2 Years

xxx

Success Rate

10/13 ratings generated profit

Average Return

+31.62%

assigned a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.92% of your transactions generating a profit, with an average return of +31.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACLX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ACLX has received 27 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ACLX average Analyst price target in the past 3 months is 111.09.

Each month's total comprises the sum of three months' worth of ratings.

ACLX Financial Forecast

ACLX Earnings Forecast

Next quarter’s earnings estimate for ACLX is -$1.02 with a range of -$1.27 to -$0.74. The previous quarter’s EPS was -$1.13. ACLX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year ACLX has Outperformed its overall industry.

ACLX Sales Forecast

Next quarter’s sales forecast for ACLX is $12.87M with a range of $4.00M to $30.00M. The previous quarter’s sales results were $8.13M. ACLX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.34% of the time in the same period. In the last calendar year ACLX has Outperformed its overall industry.

ACLX Stock Forecast FAQ

What is ACLX’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcellx Inc’s 12-month average price target is 111.09.

What is ACLX’s upside potential, based on the analysts’ average price target?

Arcellx Inc has 79.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACLX a Buy, Sell or Hold?

Arcellx Inc has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.

What is Arcellx Inc’s price target?

The average price target for Arcellx Inc is 111.09. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $121.00 ,the lowest forecast is $93.00. The average price target represents 79.38% Increase from the current price of $61.93.

What do analysts say about Arcellx Inc?

Arcellx Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of ACLX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Arcellx Inc (ACLX) Stock Forecast & Price Target

ACLX Analyst Ratings

ACLX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcellx Inc

ACLX Analyst Recommendation Trends

ACLX Financial Forecast

ACLX Earnings Forecast

ACLX Sales Forecast

ACLX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts